211 related articles for article (PubMed ID: 8574158)
21. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
Hasselbalch HC
Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
[TBL] [Abstract][Full Text] [Related]
22. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
Löfvenberg E; Wahlin A
Eur J Haematol; 1988 Oct; 41(4):375-81. PubMed ID: 3197824
[TBL] [Abstract][Full Text] [Related]
23. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis.
Chott A; Gisslinger H; Thiele J; Fritz E; Linkesch W; Radaszkiewicz T; Ludwig H
Br J Haematol; 1990 Jan; 74(1):10-6. PubMed ID: 2310690
[TBL] [Abstract][Full Text] [Related]
24. [Myeloproliferative neoplasms: recent progresses in therapy].
Kamiunten A; Shide K; Shimoda K
Rinsho Ketsueki; 2018; 59(6):741-746. PubMed ID: 29973454
[TBL] [Abstract][Full Text] [Related]
25. Circulating erythroid progenitors in patients with 'spent' polycythaemia vera and myelofibrosis with myeloid metaplasia.
Kornberg A; Fibach E; Treves A; Goldfarb A; Rachmilewitz EA
Br J Haematol; 1982 Dec; 52(4):573-8. PubMed ID: 7138787
[TBL] [Abstract][Full Text] [Related]
26. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
27. Moving toward disease modification in polycythemia vera.
Bewersdorf JP; How J; Masarova L; Bose P; Pemmaraju N; Mascarenhas J; Rampal RK
Blood; 2023 Nov; 142(22):1859-1870. PubMed ID: 37729609
[TBL] [Abstract][Full Text] [Related]
28. Polycythaemia vera: bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan.
Kreft A; Nolde C; Büsche G; Buhr T; Kreipe H; Georgii A
Eur J Haematol; 2000 Jan; 64(1):32-41. PubMed ID: 10680703
[TBL] [Abstract][Full Text] [Related]
29. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.
Weinfeld A; Swolin B; Westin J
Eur J Haematol; 1994 Mar; 52(3):134-9. PubMed ID: 8168592
[TBL] [Abstract][Full Text] [Related]
30. [Polycythaemia vera--diagnosis and therapy].
Lechner K; Geissler K; Gisslinger H
Wien Klin Wochenschr; 1999 Aug; 111(15):582-9. PubMed ID: 10483672
[TBL] [Abstract][Full Text] [Related]
31. Polycythaemia vera and essential thrombocythaemia in the elderly.
van Genderen PJ; Troost MM
Drugs Aging; 2000 Aug; 17(2):107-19. PubMed ID: 10984199
[TBL] [Abstract][Full Text] [Related]
32. [Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera].
Roche-Lestienne C; Andrieux J
Pathol Biol (Paris); 2007 Feb; 55(1):49-55. PubMed ID: 16901657
[TBL] [Abstract][Full Text] [Related]
33. Acute myelofibrosis: response to recombinant human interferon alpha-2a.
List AF; Kummet TD; Kerr DM
Leuk Res; 1990; 14(4):321-6. PubMed ID: 2332985
[TBL] [Abstract][Full Text] [Related]
34. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.
Ellis JT; Peterson P; Geller SA; Rappaport H
Semin Hematol; 1986 Apr; 23(2):144-55. PubMed ID: 3704666
[TBL] [Abstract][Full Text] [Related]
35. The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera.
Castello G; Lerza R; Cerruti A; Cavallini D; Bogliolo G; Pannacciulli I
Br J Haematol; 1994 Jul; 87(3):621-3. PubMed ID: 7993806
[TBL] [Abstract][Full Text] [Related]
36. Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Spohr M; Diehl V; Zankovich R; Niederle N; Leder LD
Br J Haematol; 2000 Jan; 108(1):64-71. PubMed ID: 10651725
[TBL] [Abstract][Full Text] [Related]
37. Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia.
Carneskog J; Kutti J; Wadenvik H; Lundberg PA; Lindstedt G
Eur J Haematol; 1998 May; 60(5):278-82. PubMed ID: 9654156
[TBL] [Abstract][Full Text] [Related]
38. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
39. Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients.
Herishanu Y; Lishner M; Bomstein Y; Kitay-Cohen Y; Fejgin MD; Gaber E; Amiel A
Cancer Genet Cytogenet; 2001 Jul; 128(2):154-7. PubMed ID: 11463455
[TBL] [Abstract][Full Text] [Related]
40. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
